In the run-up to the 2025 edition of the North American Sustainability & Responsibility Summit series we spoke with Jessica Monserrate and Jordan Keller of BASF, a 150-year-old chemical company with 111,000 employees working in 230 production and R&D sites in 90 countries. BASF is committed to ambitious sustainability targets, including a 25% reduction in Scope 1 and 2 greenhouse gas emissions by 2030 and achieving net zero across all scopes by 2050. In this wide-ranging conversation, we explore how BASF

is driving sustainability, which role renewable carbon plays, the importance of mass balance and agriculture, and how all of these efforts can provide significant benefits to both customers and the environment. For all this and more, give this episode a listen!

--

Jessica Monserrate
Head of Sustainability Agricultural Solutions, NA
BASF

Jessica has 10 years’ experience in R&D, most recently serving as Head of Microbiome Discovery and Head of Trait Engineering driving new lead discovery and improvement for Trait Research in Pest, Herbicide and Disease Control. During this time, she led the operation to manage and screen BASF’s 100,000 microbial strain collection looking for input traits and natural product chemistries for a variety of research projects. Prior to this she led the Mode of Action team for Bater as well as several global projects related to scouting for new bio-based solutions for pest control, and worked with VC fluids for the creation of new start-ups.

Most recently at BASF she worked alongside various operating divisions as a BASF R&D representative on a regional key customer account. In this role she entered various BASF R&D platforms looking for new sustainability productions to offer this key customer and co-develop biobased solutions customized for the customer’s market.

Jessica earned her Doctorate in Genetics, Cell Biology and Biochemistry from the University of California, Irvine followed by a post doctorate at Duke University studying small molecule and protein interactions. Her passion is to apply scientific innovation in solving the world’s greatest challenges and proudly represents BASF’s commitment to sustainability.

Jordan Keller
Head of Renewable Carbon NA
BASF Renewable Carbon (BReC)

Jordan Keller joined BASF twelve years ago as an engineer and has held roles of growing responsibility ever since. Today she is the Head of Renewable Carbon for North America, after more than two years as the Senior Manager Biomass Balance Solutions North America.

Jordan graduated from the University of Texas in 2013 with a degree in chemical engineering and now works for BASF in Houston.

--

BASF is a global chemical company that combines economic success with environmental protection and social responsibility. The company has around 112,000 employees in more than 90 countries, managing over 230 production sites, including 6 Verbund sites. In the United States, BASF runs over 100 production and research and development (R&D) facilities. The company boasts a diverse portfolio of more than 45,000 products for the segments Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care, and Agricultural SolutionsIn 2023, BASF reported a turnover of 68.9 billion euros.

BASF is committed to ambitious sustainability targets, including a 25% reduction in Scope 1 and 2 greenhouse gas emissions by 2030 and achieving net zero across all scopes by 2050.

In terms of the circular economy, BASF is committed to decoupling growth from resource consumption. The company aims to generate sales of € 10 billion from Loop Solutions for our customers by 2030 (2023: €5 billion). This encompasses revenue from circular products, which are based on renewable or recycled materials or support the recycling proces

In the run-up to the 2025 edition of the Medical Device Manufacturing Excellence Summit series we spoke with Shawn McCarthy, Jessica Swanson, and Peggy Hansen of Regenity Biosciences about exciting developments in the Medical Device space, with a particular emphasis on both the power of collaboration and the importance of a regulatory strategy. Regenity is an industry-leading CDMO working with 120 different industry partners and offering special expertise in regenerative devices. In this wide-ranging conversation we talk about industry trends, how medical device manufacturers are evolving to continue to meet the needs of patients, and also about some of the big ideas Regenity wants to share with the executives attending MDMES25. For all this and more, give this episode a listen!

--

Regenity Biosciences, a Linden Capital Partners portfolio company, is a leading global developer and manufacturer of bioresorbable technologies to repair and regenerate natural tissue and bone for a variety of markets including dental, spine, orthopedic, sports medicine, advanced wound, neurosurgery, ENT, and nerve repair. Founded in 1997, Regenity (formerly Collagen Matrix, Inc.) is headquartered in Paramus, New Jersey, with manufacturing locations in Oakland and Allendale, New Jersey and Groningen, the Netherlands. Regenity’s product portfolio includes a variety of collagen-based and synthetic polymer solutions that support the company’s platform for tissue and bone regeneration. Regenity develops proprietary products that are sold to OEM customers on either a contract or private label basis and offers partnership opportunities including contract product development and manufacturing services. For more information, please visit www.regenity.com.

There is a podcast Executive Platforms would like to bring to the attention of our network of senior executives. For everyone interested in online speech, especially issues like trust and safety, content moderation, regulations and compliance, and how technology is changing the way people engage with one another, we recommend the Ctrl-Alt-Speech Podcast co-hosted by Techdirt’s Mike Masnick and Everything in Moderation’s Ben Whitelaw. In this episode we talk about how the podcast came to be, what it hopes to do to help people navigate the evolving landscape of online speech, and what business leaders especially should be thinking about and learning about to prepare their organizations for a new and changing reality, with all that means for the future of commerce. For all this and more, give this episode a listen!

Mike Masnick
Co-Host, Ctrl-Alt-Speech Podcast
CEO and Founder, Techdirt

Ben Whitelaw
Co-Host, Ctrl-Alt-Speech Podcast
Editor, Everything in Moderation

At the 2024 edition of the Biomanufacturing World Summit series we sat down with Diluks de Silva to talk about Cell and Gene Therapies. For many years we have been hearing these and other Advanced Therapy Medicinal Products (ATMPs) are moving towards commercialization, and each individual therapy that has been approved is heralded as a pioneer to be celebrated and studied for lessons learned and best practices. This year something like 40 cell and gene therapies came to market, and by every indication this is just the start of a whole new generation of medicine about to help patients around the world. What does that look like on the ground? What is the industry doing to prepare itself for what comes next? How do you control things like cost and scalability while you are still inventing how to manufacture the new therapies in the first place? How are these innovations pairing with medical devices, and what does that mean for the future of medicine? There is so much good work being done, and so much still to do. As always, the experts at Compliance Architects have a comprehensive understanding of where the industry is, where it is going, and what needs to happen to ensure everyone’s success. For everyone looking for the updates that matter most on this exciting frontier of medicine, give this episode a listen!

--

Diluks De Silva
Vice President
Compliance Architects LLC

--

Compliance Architects LLC

Compliance Architects LLC delivers high-value compliance, quality, and regulatory consulting services to companies directly regulated by the U.S. FDA and other global regulatory authorities. With capabilities ranging from quality systems implementations to audits, inspection readiness, enforcement remediation, and outsourced compliance services, Compliance Architects LLC has the experience, expertise, and delivery capability to significantly improve your company’s business outcomes. Jack Garvey is CA’s founder and CEO, a chemical engineer and a practicing regulatory attorney, and has spent his entire career helping companies navigate the challenges at the intersections of science, engineering, business, and law.

At the 2024 edition of the Biomanufacturing World Summit series we sat down with Hari Pujar of Tessera Therapeutics and Flagship Pioneering to offer a concise but still in-depth look at the present and future of biopharmaceutical manufacturing, especially as it relates to Advanced Therapy Medicinal Products (ATMPs). Incredible progress has been made and is being made, but of course there are bottlenecks to be addressed as the industry grows, and as these new treatments become commercially available, the issue of cost comes into sharp focus. Where does the industry find itself today, and what are its plans for tomorrow? Give this interview a listen for a terrific window into the state of an industry on the cusp of an incredibly bright future.

--

Hari Pujar
Chief Operating Officer & Operating Partner
Tessera Therapeutics & Flagship Pioneering

Hari is a biopharmaceutical executive with experience in vaccine, biologics, mRNA, small molecule, gene therapy modalities, with a passion for value creation. He has enterprise-wide experience including platform and product development, cGMP manufacturing, and commercial, with geographies spanning North and South America, Europe, and Asia.

At the 2024 edition of the Biomanufacturing World Summit series we sat down with Martin Müller and Søren Thuesen Pedersen of Novo Nordisk to talk about opportunities biopharmaceutical manufacturers have to work together to lower costs, standardize equipment, build win-win scenarios for procurement and supply chain, and similar initiatives where competitive advantage and IP are not at stake, but costs and compliance and other performance metrics can be improved through joining forces and agreeing on things collectively rather than each company having to reinvent its own wheel on every issue. Building upon their earlier presentation that covered much of the same content, we discuss what would that collaboration look like in real terms? What does getting started look like, and how can interested companies join the ongoing conversations and deliberations? For all that and more, give this episode a listen!

--

Martin Müller
Director Technology Development - AMSAT - Technology Innovation
Novo Nordisk

Martin P. Müller joined Novo Nordisk in 2014 and currently directs development projects for innovative technologies within Aseptic Manufacturing, with particular focus on formulation, filling, wash & sterilization, and environmental monitoring.

Before moving to production in Novo Nordisk, Mr. Müller has served 10 years in Device R&D, driving the digital agenda of the area, external affairs and QMS-processes and project management, among others.

Mr. Müller earned his Master of Arts from Humboldt University Berlin, Germany, and his Master of Business Administration from Copenhagen Business School, Denmark.

Søren Thuesen Pedersen
Senior Director, External Affairs Regulatory Policy and Intelligence
Novo Nordisk

Søren Thuesen Pedersen is Senior Director, External Affairs, Regulatory Policy and Intelligence at Novo Nordisk. He is a Chemical Engineer by education and has been working 30 years in Novo Nordisk. During that that time he has been engaged and lead different areas within Manufacturing, QC-Laboratory and CMC Manufacturing Development. He has been one of the founding fathers of the Novo Nordisk External Requirements’ Process; How does Novo Nordisk ensure compliance of new external requirements? Mr. Pedersen is currently responsible for the External Representation and Advocacy strategy out of Novo Nordisk’s GMP&Q area and represents Novo Nordisk in various associations ISPE, EFPIA, IFPMA and BIO. Specifically, Mr. Pedersen is a member of the EFPIA Manufacturing Quality Expert Group (MQEG) since 2019 and member of the Board of Directors in IQ Consortium.

He has furthermore been member of the Novo Nordisk Board of Directors for 12 years as an elected employee representative.

His spare time interests include Danish and EU Politics.

For this special episode of Executive Platforms' bluEPrint Podcast series we had some of the most senior speakers and delegates from the 2024 edition of the long-running Biomanufacturing World Summit series sit down and speak to the challenges and opportunities submitted by attendees of the event as they filled out their delegate profiles, weighted by popularity.

With topics ranging from leadership and culture, to talent attraction, development and retention, to supply chain issues, to commercializing CGTs and other ATMPs, change and disruption throughout the business landscape, and how to serve patients better now and in the future, this wide-ranging conversation sees five senior executives from five very different companies speaking to the issues, ideas, innovations, and inspirations that matter to all of them as guided by a moderator who knows the industry inside and out. It is a fantastic deep dive into what is most relevant to biopharma technical operations leaders today. Give it a listen!

Our roundtable panelists are…

Moderator:

Pascal Bécotte
Managing Director
Russell Reynolds

Panelists:

Jerry Murry
Senior Vice President, Process Development
Amgen

Tongtong Wang
Senior Vice President, Global Head Technical Development
Roche

Chris Horan
Chief Technical Operations Officer
Artiva Biotherapeutics

Aine Hanly
CTO
Vir Biotechnology

Tina Self
Senior Vice President, Global Biologics Manufacturing & Berkeley Site Head
Bayer

At the 2024 edition of the North American Supply Chain Executive Summit series we sat down with two of Ernst & Young LLP’s supply chain leaders to talk about how AI is shaping supply chain operations today, what we can look forward to in the near future, and also where our current use cases are tempering some of the more hyperbolic expectations while also illustrating real-world capabilities that are going to change the way businesses approach data-intensive tasks throughout their value chain and S&OP processes. Takshay Aggarwal and Parag Jategaonkar have more than 45 years of experience between them helping companies bring new technologies into their existing systems and processes, and their enthusiasm for where AI can transform supply chains is palpable. To hear what they have to say, give this episode a listen!

--

Takshay Aggarwal
EY Americas Supply Chain Growth Platforms Leader
Ernst & Young LLP

Takshay leads Supply Chain Growth Platforms and Alliances for the EY Americas Supply Chain and Operations practice. Takshay brings over 20 years of end-to-end supply chain experience in consumer products, retail, automotive, industrial and life sciences. He’s helped companies transform their operating models to provide better customer experiences and improve their productivity by leveraging technology and artificial intelligence capabilities using cloud and platform approaches. Takshay helps clients gain a competitive advantage via digital and analytics while becoming more agile.

Parag Jategaonkar
US End to End Supply Chain Strategy and Transformation Leader
Ernst & Young LLP

Parag is an innovative, people-oriented leader with over 25 years of management consulting experience helping clients improve business performance and achieve their goals.

--

Ernst & Young LLP

In Consulting, we are building a better working world by transforming businesses through the power of people, technology and innovation.

The diversity and skills of 70,000+ people will help clients realize transformation by putting humans at the center, delivering technology at speed and leveraging innovation at scale.

www.ey.com/en_gl